Hi Eire - nice to see some optimism and a positive post. I share your sentiments. I know the company has spoken about - "our new singular focus in structural heart repair" - however there seems to be a bit of a contradiction there as evidenced in the following response to a query I lodged recently - "Both of these opportunities fall under their ADAPT® technology. The first is the use of the technology on Dural Repair (tissue surrounding spinal cord) and second is the use of the technology on hernia (soft tissue) repair." Whilst our focus at the moment may be on the TAVR project I hope that we do progress the other two at some future stage and therefore not be reliant on a single product. I am changing my sentiment to "Buy" based on the results achieved to date and the current share price but expect it will be some years down the track before we get a return.
AHZ Price at posting:
$7.83 Sentiment: Buy Disclosure: Held
(20min delay)